DBV Technologies (NASDAQ:DBVT) Earns "Market Outperform" Rating from JMP Securities

DBV Technologies (NASDAQ:DBVT - Get Free Report)'s stock had its "market outperform" rating reiterated by research analysts at JMP Securities in a note issued to investors on Thursday,Benzinga reports. They presently have a $21.00 price objective on the stock. JMP Securities' price target would indicate a potential upside of 131.79% from the stock's previous close.

DBVT has been the subject of several other reports. HC Wainwright lifted their price objective on DBV Technologies from $7.00 to $16.00 and gave the stock a "buy" rating in a research report on Monday, May 5th. Wall Street Zen upgraded DBV Technologies from a "sell" rating to a "hold" rating in a report on Friday, May 9th. The Goldman Sachs Group raised DBV Technologies to a "sell" rating and set a $7.25 price target on the stock in a research note on Thursday, May 29th. Finally, Citigroup restated an "outperform" rating on shares of DBV Technologies in a report on Tuesday, May 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $14.75.

DBV Technologies Trading Up 4.9%

NASDAQ:DBVT traded up $0.42 on Thursday, reaching $9.06. 12,837 shares of the stock traded hands, compared to its average volume of 190,017. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $12.78. The company's 50 day moving average is $9.19 and its 200-day moving average is $6.20. The firm has a market capitalization of $248.15 million, a price-to-earnings ratio of -1.84 and a beta of -0.63.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last posted its quarterly earnings data on Friday, April 11th. The company reported ($1.10) EPS for the quarter. The firm had revenue of $0.51 million during the quarter. DBV Technologies had a negative net margin of 3,249.99% and a negative return on equity of 278.24%. On average, equities research analysts forecast that DBV Technologies will post -7.05 EPS for the current fiscal year.

Institutional Trading of DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC acquired a new stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent filing with the Securities & Exchange Commission. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.